Abbvie's top product Humira
AbbVie’s Humira has increased its revenue from 2011 to 2017, generating 7.9 billion U.S. dollars in 2011 and 18.4 billion U.S. dollars in 2017. Humira is expected to continue its success in the near future. It is projected to maintain such high revenues until 2020 worldwide. In the United States, AbbVie expended 426 million U.S. dollars on advertising for Humira in 2016.
Adalimumab is marketed as Humira, a biotech pharmaceutical product. The name “Humira” is derived from “human monoclonal antibody in rheumatoid arthritis”. The inhibiting anti-inflammatory drug acts by inhibiting the activation of tumor necrosis factor-alpha (TNF) which can downregulate inflammation caused by autoimmune diseases. For example, it can be used for rheumatoid arthiritis which attacks the joints and can also impact tissues and organs. Humira can be also be used for diseases such as Plaque psoriasis and Crohn’s disease. Monthly purchases of Humira can cost some 2,700 U.S. dollars, as of 2015.